These data suggested that fully activated α-SMA+ HSCs produce a large amount of TGF-β that subsequently deactivates NK cells and inhibits their anti-fibrotic effect, particularly in advanced LC patients. The gene discussed is TGFB1; the disease is laryngotracheoesophageal cleft.